SCHEMBL16675779

SCHEMBL16675779

OCc1cccc(-c2cccnc2F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.51
CYP11B2 P19099 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA7 P36544 1/20 0.44
FYN P06241 4/20 0.44
MTOR P42345 1/20 0.44
LRRK2 Q5S007 1/20 0.43
NPY5R Q15761 1/20 0.42
DHODH Q02127 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
MAPT P10636 1/20 0.41
CDK8 P49336 1/20 0.40
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
GSK3B P49841 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
MAP2K4 P45985 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5680280 0.81 EPHB4 (0.45) CYP11B2DHODHGSK3B
SCHEMBL2372209 0.77 CYP11B2 (0.48) CYP11B2LRRK2DHODHMAPTGSK3B
SCHEMBL15726492 0.77 PRKCI (0.47) PRKCICHRNB4CHRNA3CHRNA7FYN
SCHEMBL931989 0.77 PRKCI (0.51) PRKCICHRNB4CHRNA3CHRNA7FYN
SCHEMBL16675761 0.77 PRKCI (0.47) PRKCICYP11B2CHRNB4CHRNA3CHRNA7
SCHEMBL3876408 0.77 DHODH (0.50) CYP11B2DHODHMAPT
SCHEMBL31051044 0.77 DHODH (0.50) CYP11B2DHODHMAPT
SCHEMBL2130914 0.75 PRKCI (0.61) PRKCICHRNB4CHRNA3CHRNA7FYN
SCHEMBL16675773 0.75 PRKCI (0.45) PRKCICHRNB4CHRNA3CHRNA7FYN
SCHEMBL15498628 0.75 PRKCI (0.55) PRKCICHRNB4CHRNA3CHRNA7FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2855489-B1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2017-01-04 EP disclosed
US-9518064-B2 Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-13 US disclosed
US-9518064-B2 Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-13 US disclosed
US-20150119390-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL-MYERS SQUIBB COMPANY 2015-04-30 US disclosed
US-20150119390-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL-MYERS SQUIBB COMPANY 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119390-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, F2RL1 PRKCI 3236/4885CYP11B2 1370/4885CHRNB4 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.